Ilona Tala

Ilona Tala, Ph.D has an extensive work experience in the field of pharmaceuticals and oncology. Their most recent position is as the Director of Companion Diagnostics Strategy at Servier Pharmaceuticals, which they started in 2022. Prior to that, they held roles at Daiichi Sankyo, Inc. as the Associate Director of Global Oncology CDx Lead and Associate Director of Global Oncology CDx Project Management. Ilona also worked at Novartis as the Experimental Global Biomarker Trial Manager and Sr. Biosample Clinical Manager. Additionally, they have experience in translational cell therapy as a Scientist at the New York Blood Center and as a Graduate Research Fellow investigating Chronic Myelogenous Leukemia at Rutgers Cancer Institute of New Jersey. Their earlier work includes volunteer research at Rutgers Cancer Institute of New Jersey and undergraduate research at Montclair State University.

Ilona Tala, Ph.D has a Doctor of Philosophy (Ph.D.) degree in Oncology and Cancer Biology from UMDNJ/Rutgers. Ilona also has a Bachelor of Science (B.S.) degree in Molecular Biology from Montclair State University.